Legend Biotech (LEGN) Operating Leases (2019 - 2026)

Legend Biotech (LEGN) has 8 years of Operating Leases data on file, last reported at $112.1 million in Q1 2026.

• Quarterly Operating Leases rose 116.73% year-over-year to $112.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $112.1 million (up 116.73% YoY) and the FY2025 annual result came in at $87.2 million, up 95.52% from the prior year.
• Operating Leases grew to $112.1 million in Q1 2026, from $87.2 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $112.1 million in Q1 2026 to a low of $23.6 million in Q4 2022.
• A 5-year average of $56.3 million and a median of $44.9 million in 2024 frame the typical range for Operating Leases.
• Annual changes were most pronounced in 2022 — Operating Leases surged 842.57% — and 2024, when it dropped 0.9%.
• Tracing LEGN's Operating Leases over 5 years: stood at $23.6 million in 2022, then soared by 87.14% to $44.2 million in 2023, then gained by 0.98% to $44.6 million in 2024, then surged by 95.52% to $87.2 million in 2025, then rose by 28.56% to $112.1 million in 2026.
• The last three Operating Leases figures came in at $112.1 million (Q1 2026), $87.2 million (Q4 2025), and $88.1 million (Q3 2025), per Business Quant data.